Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Front Public Health ; 10: 865855, 2022.
Article in English | MEDLINE | ID: covidwho-1952803

ABSTRACT

Background: Although coronavirus disease 2019 (COVID-19) is considered to be a disease that mainly involves the respiratory system, an increasing number of studies have reported that COVID-19 patients had pancreatic enzymes (PE) elevation and even pancreatic injury. The study aims to determine the prevalence of PE elevation, and the relationship between elevated PE and prognosis in COVID-19 patients. Methods: A comprehensive literature search was conducted according to the PRISMA guideline in PubMed, Embase, Scopus, Web of Science, and Google Scholar for studies reporting PE elevation in patients with COVID-19 from 1st January 2020 to 24th November 2021. Results: A total of 13 studies (24,353 participants) were included in our review. The pooled prevalence of PE elevation in COVID-19 patients was 24% (18%-31%), the pooled odds ratio (OR) of mortality was 2.5 (1.7-3.6), the pooled OR of ICU admission was 4.4 (2.8-6.8), and the pooled OR of kidney injury, respiratory failure and liver injury were 3.5 (1.6-7.4), 2.0 (0.5-8.7), and 2.3 (1.4-3.9) respectively. In addition, the subgroup analysis revealed that although PE elevated to > 3 × upper normal limit (ULN) was significantly related to the mortality (OR = 4.4, 2.1-9.4), it seemed that mild elevation of PE to 1-3 ULN also had a considerable risk of mortality (OR = 2.3, 1.5-3.5). Conclusions: PE elevation was a common phenomenon in patients with COVID-19, and was associated with poor clinical outcomes. However, due to the limited numbers of included studies, the result of our study still needed to be validated. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=295630, identifier: CRD42021295630.


Subject(s)
COVID-19 , COVID-19/epidemiology , Humans , Prevalence
2.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-315702

ABSTRACT

Background: Although the existing cases of COVID-19 in China have been reducing since late February 2020, the confirmed cases are surging abroad. Improving public knowledge regarding COVID-19 is critical to control the epidemic. The study aimed to determine the China’s public knowledge of COVID-19 and attitude towards the control measures. Methods: A cross-sectional study was conducted in 48 hours, from 29 February 2020, 22:30 to 2 March 2020, 22:30, based on a self-administered web-based questionnaire. The survey was conducted on the WeChat network. Exponential non-discriminative snowball sampling were applied. The questionnaire was voluntarily submitted by WeChat users. The questionnaire covered the basic demographic information, public knowledge about epidemiological and clinical characteristics of COVID-19, psychological state, and attitude towards overall control measures. The primary outcome was the Chinese public knowledge regarding COVID-19 and the attitude towards the control measures and secondary outcome was psychological state of the public during this epidemic. Results: The study included 10,905 participants and 10,399 valid questionnaires were included for analysis. Participants with tertiary education, younger age and healthcare workers had better overall knowledge compared with other participants (all P<0.05). About 91.9% of the participants believed in person-to-person transmission and 39.1% believed in animal-to-person transmission. No significant correlation between anxiety and regional number of existing cases was found, while participants in Hubei were more anxious than those in other regions. In general, 74.1% of participants acknowledged the effectiveness of overall control measures and it was negatively correlated with regional number of existing cases (r=-0.492, P=0.007). Conclusions: In conclusion, the survey revealed that Chinese public had overall good knowledge regarding COVID-19 except for those indeterminate knowledge. With the dynamic change of global epidemic situation and more researches, further study would be conducted to explore the change of public knowledge and attitude about COVID-19 in the future.

3.
J Food Biochem ; 46(5): e14085, 2022 05.
Article in English | MEDLINE | ID: covidwho-1673175

ABSTRACT

SARS-CoV-2 wreaks havoc around the world, triggering the COVID-19 pandemic. It has been confirmed that the endoribonuclease NSP15 is crucial to the viral replication, and thus identified as a potential drug target against COVID-19. The NSP15 protein was used as the target to conduct high-throughput virtual screening on 30,926 natural products from the NPASS database to identify potential NSP15 inhibitors. And 100 ns molecular dynamics simulations were performed on the NSP15 and NSP15-NPC198199 system. In all, 10 natural products with high docking scores with NSP15 protein were obtained, among which compound NPC198199 scored the highest. The analysis of the binding mode between NPC198199 and NSP15 found that NPC198199 would form H-bond interactions with multiple key residues at the catalytic site. Subsequently, a series of post-dynamics simulation analyses (including RMSD, RMSF, PCA, DCCM, RIN, binding free energy, and H-bond occupancy) were performed to further explore inhibitory mechanism of compound NPC198199 on NSP15 protein at the molecular level. The research strongly indicates that the 10 natural compounds screened can be used as potential inhibitors of NSP15, and provides valuable information for the subsequent drug discovery of anti-SARS-CoV-2. PRACTICAL APPLICATIONS: Natural products play an important role in the treatment of many difficult diseases. In this study, high-throughput virtual screening technology was used to screen the natural product database to obtain potential inhibitors against endoribonuclease NSP15. The binding mechanism between natural products and NSP15 was investigated at the molecular level by molecular dynamics technology so that it is expected to become candidate drugs for the treatment of SARS-CoV-2. We hope that our research can provide new clue to combat COVID-19 and overcome the epidemic situation as soon as possible.


Subject(s)
Antiviral Agents , Biological Products , Endoribonucleases , SARS-CoV-2 , Viral Nonstructural Proteins , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Biological Products/pharmacology , COVID-19/drug therapy , Endoribonucleases/antagonists & inhibitors , Humans , Molecular Docking Simulation , Molecular Dynamics Simulation , SARS-CoV-2/drug effects , Viral Nonstructural Proteins/antagonists & inhibitors
4.
Heart Surg Forum ; 24(5): E906-E908, 2021 Oct 21.
Article in English | MEDLINE | ID: covidwho-1502125

ABSTRACT

Coronavirus disease 2019 (COVID-19) is a highly contagious respiratory disease that threatens global health. During the pandemic period of COVID-19, the task for prevention in the general ward of cardiovascular surgery is fairly arduous. The present study intends to summarize our experience with infection control, including ward setting, admission procedures, personnel management, health education, and so on, to provide references for clinical management.


Subject(s)
COVID-19/prevention & control , Cardiac Surgical Procedures/standards , Cardiovascular Diseases/epidemiology , Guidelines as Topic , Pandemics/prevention & control , Patients' Rooms/standards , Tertiary Care Centers , COVID-19/epidemiology , Cardiovascular Diseases/surgery , China/epidemiology , Comorbidity , Humans , Retrospective Studies , SARS-CoV-2
5.
Psychiatria Danubina ; 32(3-4):587-589, 2020.
Article in English | APA PsycInfo | ID: covidwho-1481595

ABSTRACT

On March 11, the World Health Organization (WHO) announced that the novel coronavirus disease 2019 (COVID-19) outbreak had become a global pandemic. The symptoms of COVID-19 are well known, and a range of treatments have been used to save lives. However, those who have recovered from COVID-19 may be struggling to mentally cope with what they have experienced physically. They may even develop signs and symptoms of an acute stress response, or post-traumatic stress disorder (PTSD). A question we face in the coming months is how to help survivors of severe COVID-19 recover. Although patients with confirmed or suspected cases of COVID-19, health care workers, and other people are showing signs of psychological problems related to the disease, survivors of previous diseases, health care workers, and front-line employees face a higher risk of infection and are more likely to be depressed, anxious, or even diagnosed with PTSD. Exposure, fear, isolation, loss of income, reduced autonomy, and the inability of health care professionals to cure coronavirus infections contribute to this increased stress. As everyone is vulnerable to COVID-19, providing mental health support will help people maintain their mental health and return to a heathy life more quickly. The objective of this paper is to explore the research progress of post-traumatic stress disorder (PTSD) related to COVID-19. (PsycInfo Database Record (c) 2021 APA, all rights reserved)

6.
BMC Public Health ; 21(1): 471, 2021 03 09.
Article in English | MEDLINE | ID: covidwho-1127701

ABSTRACT

BACKGROUND: Although the number of existing cases of coronavirus disease 2019 (COVID-19) in China has been decreasing since late February 2020, the number of confirmed cases abroad is surging. Improving public knowledge of COVID-19 is critical to controlling the pandemic. This study aimed to determine China's public knowledge of COVID-19 and the attitudes towards control measures. METHODS: A cross-sectional study was conducted over 48 h from 22:30 29 February 2020 to 22:30 2 March 2020 based on a self-administered web-based questionnaire. The survey was conducted on the WeChat network. Exponential non-discriminative snowball sampling was applied. The questionnaire was voluntarily completed by WeChat users. The questionnaire covered basic demographic information, public knowledge of the epidemiological and clinical characteristics of COVID-19, psychological state, and attitudes towards the overall control measures. The primary outcome was the China's public knowledge of COVID-19 and the attitudes towards control measures and secondary outcome was the psychological state of the public during this pandemic. RESULTS: The study included 10,905 participants and 10,399 valid questionnaires were included for analysis. Participants with tertiary education, younger participants and healthcare workers had better overall knowledge than other participants (all P < 0.05). Approximately 91.9% of the participants believed in person-to-person transmission and 39.1% believed in animal-to-person transmission. No significant correlation between anxiety and the number of regional existing confirmed cases was found, while participants in Hubei were more anxious than those in other regions. In general, 74.1% of the participants acknowledged the effectiveness of the overall control measures, and the percentage of participants with agreement with the overall control measures was negatively correlated with the number of regional existing confirmed cases (r = - 0.492, P = 0.007). CONCLUSIONS: In conclusion, the survey revealed that the Chinese public had overall good knowledge of COVID-19 except for those indeterminate knowledges. With dynamic changes in the global pandemic situation and more research, further studies should be conducted to explore changes in public knowledge and attitudes towards COVID-19 in the future. The media could be used in a strict and regular manner to publicize knowledge of such pandemics to halt their spread.


Subject(s)
COVID-19 , Health Knowledge, Attitudes, Practice , COVID-19/epidemiology , China/epidemiology , Cross-Sectional Studies , Female , Humans , Internet , Male , Pandemics , SARS-CoV-2 , Surveys and Questionnaires
7.
Wien Klin Wochenschr ; 132(21-22): 677-684, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-996395

ABSTRACT

OBJECTIVE: To summarize the successful experience of timely crisis management, correct measures, and successful display of the hospital image in the First Affiliated Hospital of Zhejiang University (FAHZU), to improve the ability of emergency response. METHODS: The FAHZU, as the earliest designated hospital, accomplished the transformation from general hospital to infectious disease hospital under the guiding ideology of centralized patients, centralized experts, centralized resources, and centralized treatment with measures to transfer the Zhijiang campus hospitalized patients quickly, complete the space layout, create diagnosis and treatment space, streamline logistics, and transform logistics facilities within 48 h. As of 5 March, the hospital had admitted 104 patients. RESULTS: Of the severe cases in Zhejiang province 95% underwent centralized treatment with the goal of zero deaths for severely ill patients, zero misdiagnoses for infected patients, and zero infections for medical staff, and this served as a reference for large medical institutions regarding how to manage such a public health emergency. CONCLUSION: The successful cases of FAHZU provided a valuable experience for large medical institutions on how to address public health emergencies and how to carry out diagnosis and treatment and streamline the layout and related facilities in emergency reconstruction.


Subject(s)
Betacoronavirus , Coronavirus Infections , Emergencies , Pandemics , Pneumonia, Viral , COVID-19 , Hospitals, General , Humans , SARS-CoV-2
9.
SSRN; 2020.
Preprint | SSRN | ID: ppcovidwho-653

ABSTRACT

Background: Wenzhou City in Zhejiang Province, China is a non-municipal municipality with the worst outbreak of 2019 novel coronavirus disease (COVID-19) outsid

10.
Int J Med Sci ; 17(15): 2373-2378, 2020.
Article in English | MEDLINE | ID: covidwho-761077

ABSTRACT

Background: In patients with coronavirus disease 2019 (COVID-19) pneumonia, whether new pulmonary lesions will continue to develop after treatment was unknown. This study aimed to determine whether new pulmonary lesions will develop after treatment in patients with COVID-19 pneumonia, and investigate their CT features and outcomes. Methods: This retrospective study included 56 consecutive patients with confirmed COVID-19 pneumonia from January 20 to March 5, 2020. Their initial and follow-up CT images and clinical data were reviewed. The CT manifestations of primary and newly developed pulmonary lesions and their changes after treatment were mainly evaluated. Results: Among the 56 patients (mean age: 48±15 years, 35 men) with COVID-19 pneumonia, 42 (75.0%) patients developed new pulmonary lesions during treatment. All new lesions developed before the nucleic acid test turned negative. Patients with new lesions were more likely to have lymphopenia (P=0.041) or increased C-reactive protein (CRP) levels (P<0.001) than those without new lesions. Of the 42 patients, 30 (71.4%) patients developed new lesions once, and 12 (28.6%) twice or thrice, which usually appeared when primary lesions were progressing (37, 88.1%) and 1-15 days after treatment. The newly developed lesions were usually multiple (38, 90.5%), distributed in the previously involved (39, 92.9%) or uninvolved (27, 64.3%) lobes, and manifested as ground-glass opacities (GGOs) with consolidation (23, 54.8%) or pure GGOs (19, 45.2%). After their occurrence, the new lesions in most patients (32, 76.2%) showed direct absorption, whereas those in some patients (10, 23.8%) progressed before absorption. Conclusion: During treatment, most patients with COVID-19 pneumonia will develop new pulmonary lesions, which usually manifest as multiple GGOs distributed around the primary lesions or in previously uninvolved lobes, and are subsequently absorbed directly.


Subject(s)
Betacoronavirus/isolation & purification , Clinical Laboratory Techniques/statistics & numerical data , Coronavirus Infections/mortality , Lung/diagnostic imaging , Pneumonia, Viral/mortality , Tomography, X-Ray Computed/statistics & numerical data , Adult , Betacoronavirus/genetics , Betacoronavirus/pathogenicity , COVID-19 , COVID-19 Testing , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Coronavirus Infections/virology , Disease Progression , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Pneumonia, Viral/virology , RNA, Viral/isolation & purification , Retrospective Studies , SARS-CoV-2
11.
J Hematol Oncol ; 13(1): 120, 2020 09 04.
Article in English | MEDLINE | ID: covidwho-744994

ABSTRACT

BACKGROUND: Critically ill patients diagnosed with COVID-19 may develop a pro-thrombotic state that places them at a dramatically increased lethal risk. Although platelet activation is critical for thrombosis and is responsible for the thrombotic events and cardiovascular complications, the role of platelets in the pathogenesis of COVID-19 remains unclear. METHODS: Using platelets from healthy volunteers, non-COVID-19 and COVID-19 patients, as well as wild-type and hACE2 transgenic mice, we evaluated the changes in platelet and coagulation parameters in COVID-19 patients. We investigated ACE2 expression and direct effect of SARS-CoV-2 virus on platelets by RT-PCR, flow cytometry, Western blot, immunofluorescence, and platelet functional studies in vitro, FeCl3-induced thrombus formation in vivo, and thrombus formation under flow conditions ex vivo. RESULTS: We demonstrated that COVID-19 patients present with increased mean platelet volume (MPV) and platelet hyperactivity, which correlated with a decrease in overall platelet count. Detectable SARS-CoV-2 RNA in the blood stream was associated with platelet hyperactivity in critically ill patients. Platelets expressed ACE2, a host cell receptor for SARS-CoV-2, and TMPRSS2, a serine protease for Spike protein priming. SARS-CoV-2 and its Spike protein directly enhanced platelet activation such as platelet aggregation, PAC-1 binding, CD62P expression, α granule secretion, dense granule release, platelet spreading, and clot retraction in vitro, and thereby Spike protein enhanced thrombosis formation in wild-type mice transfused with hACE2 transgenic platelets, but this was not observed in animals transfused with wild-type platelets in vivo. Further, we provided evidence suggesting that the MAPK pathway, downstream of ACE2, mediates the potentiating role of SARS-CoV-2 on platelet activation, and that platelet ACE2 expression decreases following SARS-COV-2 stimulation. SARS-CoV-2 and its Spike protein directly stimulated platelets to facilitate the release of coagulation factors, the secretion of inflammatory factors, and the formation of leukocyte-platelet aggregates. Recombinant human ACE2 protein and anti-Spike monoclonal antibody could inhibit SARS-CoV-2 Spike protein-induced platelet activation. CONCLUSIONS: Our findings uncovered a novel function of SARS-CoV-2 on platelet activation via binding of Spike to ACE2. SARS-CoV-2-induced platelet activation may participate in thrombus formation and inflammatory responses in COVID-19 patients.


Subject(s)
Betacoronavirus/metabolism , Blood Platelets/metabolism , Coronavirus Infections/metabolism , Peptidyl-Dipeptidase A/metabolism , Pneumonia, Viral/metabolism , Thrombosis/metabolism , Adult , Aged , Angiotensin-Converting Enzyme 2 , Animals , Betacoronavirus/genetics , COVID-19 , Caco-2 Cells , Coronavirus Infections/virology , Female , HeLa Cells , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Middle Aged , PC-3 Cells , Pandemics , Peptidyl-Dipeptidase A/genetics , Platelet Aggregation/immunology , Platelet Count , Pneumonia, Viral/virology , RNA, Viral/blood , SARS-CoV-2 , Serine Endopeptidases/metabolism , Spike Glycoprotein, Coronavirus/metabolism , Thrombosis/virology
12.
Arch Iran Med ; 23(4): 268-271, 2020 04 01.
Article in English | MEDLINE | ID: covidwho-50641

ABSTRACT

Since December 2019, there has been an outbreak of a novel coronavirus (COVID-19) infection in Wuhan, China. Meanwhile, the outbreak also drew attention and concern from the World Health Organization (WHO). COVID-19 is another human infectious disease caused by coronavirus. The transmission of COVID-19 is potent and the infection rate is fast. Since there is no specific drug for COVID-19, the treatment is mainly symptomatic supportive therapy. In addition, it should be pointed out that patients with severe illness need more aggressive treatment and meticulous care. Recently, accurate RNA detection has been decisive for the diagnosis of COVID-19. The development of highly sensitive RT-PCR has facilitated epidemiological studies that provide insight into the prevalence, seasonality, clinical manifestations and course of COVID-19 infection. In this review, we summarize the epidemiology and characteristics of COVID-19.


Subject(s)
Betacoronavirus , Coronavirus Infections , Disease Susceptibility , Pandemics , Pneumonia, Viral , Adolescent , Adult , Aged , Betacoronavirus/pathogenicity , COVID-19 , COVID-19 Testing , Child , Child, Preschool , China/epidemiology , Clinical Laboratory Techniques , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Cough/etiology , Disease Outbreaks , Female , Fever/etiology , Humans , Infant , Middle Aged , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/etiology , Pregnancy , SARS-CoV-2 , Seroepidemiologic Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL